Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case

Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study

Published:2020-06-29 Issue:3 Volume:50 Page:484-498
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Sherwood Matthew,Bliden Kevin P.,Ilkhanoff Leonard,Venkataraman Ganesh,Strickberger Adam,Yazdani Sharam,McSwain Robert,Rashid Haroon,Navarese Eliano P.,Plummer Tracy,Batchelor Wayne,Chaudhary Rahul,Tantry Udaya S.,Gurbel Paul A.^ORCID

Funder

Boston Scientific Corporation

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

https://link.springer.com/content/pdf/10.1007/s11239-020-02205-5.pdf

Reference32 articles.

1. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr, Prevail IPA (2017) 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 70(24):2964–2975. https://doi.org/10.1016/j.jacc.2017.10.021

2. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY (2014) Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64(1):1–12. https://doi.org/10.1016/j.jacc.2014.04.029

3. Belgaid DR, Khan Z, Zaidi M, Hobbs A (2016) Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. Int J Cardiol 219:177–179. https://doi.org/10.1016/j.ijcard.2016.06.041

4. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D, Investigators PA (2013) Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation 127(6):720–729. https://doi.org/10.1161/CIRCULATIONAHA.112.114389

5. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Mazzone P, Foley D, Grygier M, Sievert H, De Potter T, Vireca E, Stein K, Bergmann MW, following i, institutions participated in the Es (2019) Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology. Circ Arrhythm Electrophysiol 12(4):e006841. https://doi.org/10.1161/CIRCEP.118.006841

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Association of Hematological Markers with Occurrence of Thrombotic and Bleeding Events following Left Atrial Appendage Occlusion;Cardiology;2024-07-22

2. Postoperative Coagulation Changes in Patients after Epicardial Left Atrial Appendage Occlusion Varies Based on the Left Atrial Appendage Size;Diseases;2023-12-29

3. Percutaneous Left Atrial Appendage Occlusion—Current Evidence and Future Directions;Journal of Clinical Medicine;2023-11-24

4. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure;JACC: Cardiovascular Interventions;2023-06

5. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure;Heart Rhythm;2023-05